ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Average Rating of “Moderate Buy” from Analysts

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has received a consensus rating of “Moderate Buy” from the seventeen research firms that are presently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $25.56.

A number of analysts have recently issued reports on the stock. StockNews.com upgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, September 13th. Royal Bank of Canada reduced their target price on ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Cantor Fitzgerald lowered their price target on ACADIA Pharmaceuticals from $37.00 to $28.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th. Morgan Stanley lowered shares of ACADIA Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $28.00 to $20.00 in a report on Wednesday, August 7th. Finally, Raymond James reaffirmed a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 10th.

Insider Activity at ACADIA Pharmaceuticals

In related news, CEO Stephen Davis sold 31,747 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $15.28, for a total value of $485,094.16. Following the completion of the transaction, the chief executive officer now owns 186,555 shares in the company, valued at $2,850,560.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CEO Stephen Davis sold 31,747 shares of the firm’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $15.28, for a total transaction of $485,094.16. Following the completion of the transaction, the chief executive officer now owns 186,555 shares of the company’s stock, valued at $2,850,560.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Brendan Teehan sold 9,534 shares of the firm’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $15.28, for a total transaction of $145,679.52. Following the transaction, the chief operating officer now owns 52,177 shares of the company’s stock, valued at approximately $797,264.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 51,014 shares of company stock worth $779,494 in the last three months. 28.30% of the stock is owned by company insiders.

Institutional Trading of ACADIA Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Park Place Capital Corp acquired a new stake in shares of ACADIA Pharmaceuticals during the third quarter worth approximately $25,000. Covestor Ltd grew its holdings in shares of ACADIA Pharmaceuticals by 70.5% during the 1st quarter. Covestor Ltd now owns 2,032 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 840 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of ACADIA Pharmaceuticals in the first quarter worth $48,000. Stonepine Capital Management LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the second quarter worth $81,000. Finally, Acadian Asset Management LLC acquired a new stake in ACADIA Pharmaceuticals during the second quarter valued at $111,000. 96.71% of the stock is owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Trading Up 0.9 %

ACAD stock opened at $15.30 on Friday. The firm has a 50-day moving average of $15.65 and a two-hundred day moving average of $16.25. ACADIA Pharmaceuticals has a 12 month low of $14.31 and a 12 month high of $32.59. The company has a market cap of $2.53 billion, a price-to-earnings ratio of -1,530.00, a PEG ratio of 0.49 and a beta of 0.38.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.18 by $0.02. The firm had revenue of $241.96 million during the quarter, compared to analysts’ expectations of $235.95 million. ACADIA Pharmaceuticals had a return on equity of 6.89% and a net margin of 3.43%. The business’s revenue for the quarter was up 46.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.01 earnings per share. As a group, equities analysts forecast that ACADIA Pharmaceuticals will post 0.52 earnings per share for the current year.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.